We are live on
!
Find out more
Dianthus Therapeutics
DNTH
DNTH
75 hedge funds and large institutions have $51.9M invested in Dianthus Therapeutics in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 20 increasing their positions, 20 reducing their positions, and 31 closing their positions.
New
Increased
Maintained
Reduced
Closed
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 20
0.25% less ownership
Funds ownership: 5.09% → 4.84% (-0.25%)
19% less funds holding
Funds holding: 93 → 75 (-18)
52% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 31
63% less capital invested
Capital invested by funds: $139M → $51.9M (-$87M)
Holders
75
Holders Change
-18
Holders Change %
-19.35%
% of All Funds
1.26%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
20
Reduced
20
Closed
31
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$1.68M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$900K |
| 3 |
Renaissance Technologies
New York
|
+$760K |
| 4 |
Millennium Management
New York
|
+$728K |
| 5 |
RC
RBF Capital
San Francisco,
California
|
+$574K |
Top Sellers
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$4.07M |
| 2 |
BlackRock
New York
|
-$2.07M |
| 3 |
Principal Financial Group
Des Moines,
Iowa
|
-$1.73M |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$930K |
| 5 |
State Street
Boston,
Massachusetts
|
-$657K |
